SCHEMBL2536658

SCHEMBL2536658

CCCCc1ccc(-c2ccc(OCc3ccc(C(C)(C)C)cc3)c(CCC(=O)O)c2)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RXRA P19793 2/20 0.49
RXRB P28702 2/20 0.49
RXRG P48443 2/20 0.49
PTGER1 P34995 2/20 0.48
PTGER4 P35408 1/20 0.48
PTGER3 P43115 1/20 0.48
PTGER2 P43116 1/20 0.48
PSEN1 P49768 3/20 0.46
ALOX5 P09917 1/20 0.46
PPARD Q03181 3/20 0.46
PPARA Q07869 3/20 0.46
FFAR4 Q5NUL3 4/20 0.43
FFAR1 O14842 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43
XDH P47989 1/20 0.43
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NR1H4 Q96RI1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2537492 1.00 RXRA (0.49) RXRARXRBRXRGPTGER1PTGER4
SCHEMBL2536062 0.92 RXRA (0.53) RXRARXRBRXRGPTGER1PTGER4
SCHEMBL2534023 0.89 PTGER4 (0.55) RXRARXRBRXRGPTGER1PTGER4
SCHEMBL2534893 0.89 PPARD (0.43) RXRARXRBRXRGPTGER1PTGER4
SCHEMBL2539349 0.88 PTGER1 (0.56) RXRARXRBRXRGPTGER1PTGER4
SCHEMBL2531052 0.88 PTGER4 (0.58) RXRARXRBRXRGPTGER1PTGER4
SCHEMBL2533427 0.87 FFAR4 (0.51) RXRARXRBRXRGPTGER1PTGER4
SCHEMBL2541443 0.87 FFAR4 (0.53) RXRARXRBRXRGPTGER1PTGER4
SCHEMBL2539389 0.87 FFAR4 (0.51) RXRARXRBRXRGPTGER1PTGER4
SCHEMBL2539344 0.87 RXRA (0.50) RXRARXRBRXRGPTGER1PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044236-B2 Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-10-25 US disclosed
EP-2080751-A1 CARBOXYLIC ACID DERIVATIVE Institute of Medicinal Molecular Design, Inc. (JP) 2009-07-22 EP disclosed
US-20080275116-A1 Carboxilic acid derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275116-A1 Carboxilic acid derivatives SERPINE1, CTRL, SERPINC1 RXRA 596/4885RXRB 634/4885RXRG 1007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.